Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Elizabeth Blair   and   Ari Rosenberg.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.342
         
        
        
     
 
    
        
        - 
            Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer. Clin Cancer Res. 2025 May 27.
            
            
                Score: 0.243
            
         
        
        - 
            Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
            
            
                Score: 0.241
            
         
        
        - 
            Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
            
            
                Score: 0.228
            
         
        
        - 
            Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
            
            
                Score: 0.200
            
         
        
        - 
            Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
            
            
                Score: 0.192
            
         
        
        - 
            Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
            
            
                Score: 0.189
            
         
        
        - 
            Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits. Cureus. 2022 Jul; 14(7):e27521.
            
            
                Score: 0.050